Abstracts tagged "Juvenile idiopathic arthritis"

Abstract Number: 0874 • ACR Convergence 2022
A Tale of Many Canadas: Associations of Ethnicity with Juvenile Idiopathic Arthritis Categories and Disease Severity at Presentation in a Multicultural Universal Healthcare Setting: Results from ReACCh-Out
Stephanie Wong¹, Lori Tucker², Kristin Houghton³, David Cabral⁴, Mercedes Chan², Ross Petty³, Andrea Human², Kimberly Morishita³, Rae Yeung⁵, Kiem Oen⁶, Ciaran Duffy⁷, Roberta Berard⁸, Gaelle Chedeville⁹, Thomas Loughin¹⁰, Matthew Berkowitz¹⁰ and Jaime Guzman¹¹, ¹University of British Columbia, Vancouver, BC, Canada, ²British Columbia Children's Hospital, Vancouver, BC, Canada, ³University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁴BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁵The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁶University of Manitoba, Toronto, ON, Canada, ⁷University of Ottawa, Ottawa, ON, Canada, ⁸London Health Sciences Centre, London, ON, Canada, ⁹McGill University, Montréal, QC, Canada, ¹⁰Simon Fraser University, Vancouver, BC, Canada, ¹¹University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The distribution of Juvenile Idiopathic Arthritis (JIA) categories and disease severity at presentation vary across countries, however it is unclear how much of this…
Abstract Number: 2209 • ACR Convergence 2022
Efficacy of Secukinumab in Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis Subtypes of Juvenile Idiopathic Arthritis: Results from a Randomized, Phase 3 Study
Hermine Brunner¹, Elena Chertok², Joke Dehoorne³, Gerd Horneff⁴, Tilmann Kallinich⁵, Ingrid Louw⁶, Maria Alessio⁷, Sandrine Compeyrot-Lacassagne⁸, Bernard Lauwerys⁹, Neil Martin¹⁰, Katherine Marzan¹¹, W Patrick Knibbe¹², Ruvie Martin¹³, Xuan Zhu¹⁴, sarah whelan¹⁵, Luminita Pricop¹⁶, Daniel Lovell¹⁷, Alberto Martini¹⁸ and Nicola Ruperto¹⁹, ¹Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ²Voronezh State Medical University, Voronezh, Russia, ³University Hospital Gent, Gent, Belgium, ⁴Pediatrics, Asklepios Klinik Sankt Augustin GmbH, Sankt Augustin, Germany, ⁵Charité - Universitätsmedizin Berlin, Nuremberg, Germany, ⁶Panaroma Medical Centre, Cape Town, South Africa, ⁷Policlinico Federico II di Napoli, Napoli, Italy, ⁸Great Ormond Street Hospital for Children, London, United Kingdom, ⁹Cliniques Universitaires Saint-Luc, Brussels, Belgium, ¹⁰Royal Hospital for Children, Glasgow, Scotland, United Kingdom, ¹¹Children's Hospital Los Angeles, Los Angeles, CA, ¹²St. Luke's Hospital System, Meridian, ID, ¹³Novartis Pharmaceutical Corporation, East Hanover, NJ, ¹⁴Novartis Pharmaceuticals Corporation, Basking Ridge, NJ, ¹⁵Novartis Ireland Ltd, Crumlin, Dublin, Ireland, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁸Istituto Giannina Gaslini, Genova, Italy, ¹⁹IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) represent pediatric counterparts of adult non-radiographic axial spondyloarthritis and psoriatic…
Abstract Number: 0853 • ACR Convergence 2022
Reliability of MRI Lesions Comprising the Preliminary OMERACT Juvenile Idiopathic Arthritis MRI Score (OMERACT JAMRI-SIJ): What Is the Impact of Systematic Reader Calibration?
Walter P Maksymowych¹, Nisha Varma², Arthur Meyers³, Jennifer Stimec⁴, Nikolay Tzaribachev⁵, Jonathan Akikusa⁶, Tarimobo Otobo⁴, Marion von Rossum⁷, Andrea Doria⁴ and Nele Herregods⁸, ¹Department of Medicine, University of Alberta, Edmonton, AB, Canada, ²Department of Paediatric Radiology, The Royal Children's Hospital Melbourne, Melbourne, Australia, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Department of Diagnostic Imaging, SickKids, University of Toronto, Toronto, ON, Canada, ⁵PRI Research Institute, Bad Bramstedt, Germany, ⁶Rheumatology Service, Royal Children’s Hospital, Melbourne, Melbourne, Australia, ⁷Emma Children’s Hospital, Dept Pediatrics, Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Ghent University Hospital, Ghent, Belgium
Background/Purpose: The evaluation of the sacroiliac joints (SIJ) in children with Juvenile Idiopathic Arthritis (JIA) increasingly relies on the use of MRI since radiography is…
Abstract Number: 0875 • ACR Convergence 2022
Predictive Biomarkers of Tofacitinib Response and Disease Activity in Juvenile Idiopathic Arthritis Subtypes: A Longitudinal Study
Ekemini Ogbu¹, Sherry Thornton², Alyssa Sproles², Alexei Grom³, Sanjeev Dhakal⁴, Bin Huang⁵ and Hermine Brunner⁶, ¹Cincinnati Children's Hospital Medical Center, Atlanta, GA, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Divisions of Rheumatology, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ⁴Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cinciannati, OH, ⁶Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH
Background/Purpose: Tofacitinib has been shown to improve disease activity of several subtypes of Juvenile Idiopathic Arthritis (JIA). No known biomarkers to date predict JIA improvement…
Abstract Number: 2210 • ACR Convergence 2022
Baricitinib in Juvenile Idiopathic Arthritis: A Phase 3, Double-Blind, Placebo-Controlled, Withdrawal, Efficacy and Safety Study
Athimalaipet Ramanan¹, Pierre Quartier Dit Maire², Nami Okamoto³, Gabriella Meszaros⁴, Joana Araujo⁴, Zhongkai Wang⁴, Ran Liao⁴, Brenda Crowe⁴, Xin Zhang⁴, Rodney Decker⁴, Stuart Keller⁴, Hermine Brunner⁵ and Nicola Ruperto⁶, ¹Bristol Royal Hospital for Children, Bristol, United Kingdom, ²Necker hospital, Paris Cedex 15, France, ³Osaka Medical College, Takatsuki-city, Japan, ⁴Eli Lilly and Company, Indianapolis, IN, ⁵Division of Rheumatology, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Department of Pediatrics, Cincinnati, OH, ⁶IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Baricitinib is a JAK1/2 selective inhibitor approved for the treatment of rheumatoid arthritis. Juvenile idiopathic arthritis (JIA) is a group of diseases characterized by…
Abstract Number: 0854 • ACR Convergence 2022
Outcome of Uveitis in Juvenile Idiopathic Arthritis and Spondyloarthritis Patients – a 5-year Follow up Study
Filipe Pinheiro¹, Mariana Leuzinger-Dias², Bruno Fernandes³, Diogo Fonseca⁴, Joana Vilaça⁵, Luís Figueira⁶ and Iva Brito⁷, ¹Rheumatology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ²Ophtalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ³Rheumatology Deparment, Centro Hospitalar e Universitário de São João, Porto, Portugal, ⁴Rheumatology Department, Centro Hospitalar de Vila Nova de Gaia / Espinho, Vila Nova de Gaia, Portugal, ⁵Paediatrics Department, Hospital de Braga, Braga, Portugal, ⁶Ophthalmology Department, Centro Hospitalar Universitário de São João, Porto, Portugal, ⁷Pediatric and Young Adult Rheumatology Unit, Centro Hospitalar Universitário de São João, Porto, Portugal
Background/Purpose: Uveitis is a frequent complication of juvenile idiopathic arthritis (JIA) and juvenile spondyloarthritis (jSpA), and diagnosis is often challenging. The importance of uveitis relates…
Abstract Number: 0876 • ACR Convergence 2022
Investigation of Predictive Factors for Active Disease Status Within 24 Months of Juvenile Idiopathic Arthritis Diagnosis
Erin Balay¹ and Susan Shenoi², ¹University of Washington, Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Hospital and Research Center / University of Washington, Seattle, WA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common rheumatologic disease in children. JIA disease course and prognosis varies significantly between its seven categories, and…
Abstract Number: 2211 • ACR Convergence 2022
Identification of Plasma Metabolomic Biomarkers of Juvenile Idiopathic Arthritis
Amar Kumar¹, Joshua Tartarian², Valentina Shakhnovich³, Carl Langefeld⁴, Daniel Lovell⁵, Susan Thompson⁶, Mara Becker⁷ and Ryan Funk⁸, ¹University of Kansas, Kansas City, KS, ²University of Kansas Medical Center, Kansas City, KS, ³University of Missouri-Kansas City School of Medicine & Children’s Mercy Kansas City, Kansas City, MO, ⁴Wake Forest School of Medicine, Winston Salem, NC, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, Blue Ash, OH, ⁷Duke University Medical Center/Duke Clinical Research Institute, Durham, NC, ⁸University of Kansas, Leawood, KS
Background/Purpose: Identification of disease and therapeutic biomarkers remains a barrier to the early diagnosis of and initiation of effective therapy for juvenile idiopathic arthritis (JIA).…
Abstract Number: 0855 • ACR Convergence 2022
Change in Short Term Outcomes Following Tolerated Disease Activity Level for Individuals with Juvenile Idiopathic Arthritis in the Childhood Arthritis and Rheumatology Research Alliance Registry
Melissa Mannion¹, Fenglong Xie¹, Timothy Beukelman¹, Jeffrey Curtis² and , for the CARRA Registry Investigators³, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Alabama at Birmingham, Hoover, AL, ³CARRA, Washington, DC
Background/Purpose: Current recommendations suggest treatment escalation for juvenile idiopathic arthritis (JIA) until the disease activity target is reached, ideally inactive or low disease activity. Our…
Abstract Number: 0877 • ACR Convergence 2022
Neutrophils Extracellular Traps Formation May Serve as a Biomarker for Disease Activity in Oligoarticular Juvenile Idiopathic Arthritis
Merav Heshin-Bekenstein¹, Szilvia Baron², Grant Schulert³, Anna Shusterman⁴, Rachel Shukrun⁴, Yoav Binenbaum⁴ and Ronit Elhasid⁵, ¹Dana Dwek Children's Hospital, Tel Aviv Medical Center Israel, Binyamina, Israel, ²Pediatric Hemato-Oncology Research Laboratory, Tel Aviv Medical Center, Tel Aviv, Israel, ³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁴Tel Aviv Medical Center, Tel Aviv, Israel, ⁵Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in children, causing significant morbidity. Despite the dramatic improvement in treatment, many patients…
Abstract Number: 2213 • ACR Convergence 2022
Multi-omic Analysis of Macrophage Activation Syndrome Associated with sJIA Reveals a Potential Role of Type I Interferons in the Expansion of Cycling T Cells
Kailey Brodeur¹, Liang Chen¹, zhengping huang², Yan Du¹, Holly Wobma³, Maria Taylor⁴, Joyce Chang³, Megan Day-Lewis³, Fatma Dedeoglu³, Olha Halyabar³, Mindy Lo³, Jane W. Newburger⁵, Mary Beth F. Son³, Robert Sundel³, Peter Nigrovic³, lauren henderson³ and Pui Lee³, ¹Boston Children's Hospital, Boston, MA, ²Guangdong Second Provincial Hospital, Guangzhou, China, ³Division of Immunology, Boston Children's Hospital, Boston, MA, ⁴Division of Immunology, Boston Children's Hospital, Brighton, MA, ⁵Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Macrophage activation syndrome (MAS) is a complication of systemic juvenile idiopathic arthritis (sJIA) characterized by cytokine storm and overt immune cell activation. We aim…
Abstract Number: 0856 • ACR Convergence 2022
A Cross-Sectional Description of Physical Activity (PA) in Children with Juvenile Idiopathic Arthritis (JIA): The LEAP Study (Linking Exercise, Activity, and Pathophysiology in Canadian Children with Arthritis)
Lori Tucker¹, Jaime Guzman², Lamia Hayawi³, Nick Barrowman³, Heather Macdonald⁴, Kristin Houghton⁵, David Cabral⁶, Bianca Lang⁷, Dax Rumsey⁸, Elizabeth Stringer⁹, Shirley Tse¹⁰, Roberta Berard¹¹, Claire Leblanc¹², Tommy Gerschman¹³, Liane Heale¹⁴, Karen Watanabe-Duffy¹⁵, Sarah Campillo¹², Natalie Shiff¹⁶ and Ciaran Duffy¹⁷, ¹British Columbia Children's Hospital, Vancouver, BC, Canada, ²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada, ³Children's Hospital of Eastern Ontario Research Institute, Ottawa, ON, Canada, ⁴University of British Columbia, Vancouver, BC, Canada, ⁵University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁶BC Children's Hospital and University of British Columbia, Vancouver, BC, Canada, ⁷Dalhousie University - Halifax, Halifax, NS, Canada, ⁸Stollery Children's Hospital, Edmonton, AB, Canada, ⁹IWK Hospital, Halifax, NS, Canada, ¹⁰Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute; Department of Paediatrics, University of Toronto, Toronto, ON, Canada, ¹¹London Health Sciences Centre, London, ON, Canada, ¹²McGill University, Montréal, QC, Canada, ¹³University of British Columbia - Vancouver, North Vancouver, BC, Canada, ¹⁴McMaster University, Oakville, ON, Canada, ¹⁵Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ¹⁶Janssen Scientific Affairs, LLC, Horsham, PA, USA/ Department of Community Health and Epidemiology, College of Medicine, University of Saskatchewan, Saskatoon, Canada, Philadelphia, PA, ¹⁷University of Ottawa, Ottawa, ON, Canada
Background/Purpose: Participation in physical activity (PA) is a concern of children with JIA , however, factors associated with PA in these children are incompletely understood. …
Abstract Number: 0878 • ACR Convergence 2022
A United States Nationwide Analysis of Total Knee Arthroplasty in Patients < 21 Years Old
John Gibbons¹, Cynthia A. Kahlenberg¹, Deanna Jannat-Khah, DrPH, MSPH¹, Alexander B. Christ², Susan Goodman¹, Peter Sculco¹, Mark Figgie¹ and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Keck School of Medicine of USC, Los Angeles, CA, ³Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Total knee arthroplasty (TKA) is rarely performed in patients under 21 years old and may be performed in this population due to conditions such…
Abstract Number: PP08 • ACR Convergence 2022
Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)
Ela Chintagunta¹, Courtney Wells² and Kristine Carandang³, ¹Young Patients' Autoimmune Research & Empowerment Alliance, Chicago, IL, ²University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN, ³Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA
Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of 13 when I was experiencing joint swelling in my lower body and my…
Abstract Number: 0858 • ACR Convergence 2022
Predicting the Occurrence of Drug-Free Inactive Disease Two Years After Diagnosis of Non-Systemic Juvenile Idiopathic Arthritis
Melissa Mannion¹, Chen Chen², Olha Halyabar³, Susan Paetkau⁴, Tingting Qiu⁵ and Bin Huang⁶, ¹University of Alabama at Birmingham, Birmingham, AL, ²Cincinnati Children's Hospital Medical Center, Taipei, Taiwan, ³Children's Hospital/Boston Medical Center, Boston, MA, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ⁶Cincinnati Children's Hospital Medical Center, Cinciannati, OH
Background/Purpose: The goal of treatment for juvenile idiopathic arthritis (JIA) is inactive disease (ID), but the optimal treatment for each patient to maximize ID and…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.